Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Personalizing age of cancer screening cessation based on comorbid conditions: Model estimates of harms and benefits

    Access Status
    Fulltext not available
    Authors
    Lansdorp_Vogelaar, Iris
    Gulati, R.
    Mariotto, A.
    Schechter, C.
    De Carvalho, T.
    Knudsen, A.
    Van Ravesteyn, N.
    Heijnsdijk, E.
    Pabiniak, C.
    Van Ballegooijen, M.
    Rutter, C.
    Kuntz, K.
    Feuer, E.
    Etzioni, R.
    De Koning, H.
    Zauber, A.
    Mandelblatt, J.
    Date
    2014
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Lansdorp_Vogelaar, I. and Gulati, R. and Mariotto, A. and Schechter, C. and De Carvalho, T. and Knudsen, A. and Van Ravesteyn, N. et al. 2014. Personalizing age of cancer screening cessation based on comorbid conditions: Model estimates of harms and benefits. Annals of Internal Medicine. 161 (2): pp. 104-112.
    Source Title
    Annals of Internal Medicine
    DOI
    10.7326/M13-2867
    ISSN
    0003-4819
    URI
    http://hdl.handle.net/20.500.11937/50070
    Collection
    • Curtin Research Publications
    Abstract

    Background: Harms and benefits of cancer screening depend on age and comorbid conditions, but reliable estimates are lacking. Objective: To estimate the harms and benefits of cancer screening by age and comorbid conditions to inform decisions about screening cessation. Design: Collaborative modeling with 7 cancer simulation models and common data on average and comorbid condition level-specific life expectancy. Setting: U.S. population. Patients: U.S. cohorts aged 66 to 90 years in 2010 with average health or 1 of 4 comorbid condition levels: none, mild, moderate, or severe. Intervention: Mammography, prostate-specific antigen testing, or fecal immunochemical testing. Measurements: Lifetime cancer deaths prevented and life-years gained (benefits); false-positive test results and overdiagnosed cancer cases (harms). For each comorbid condition level, the age at which harms and benefits of screening were similar to that for persons with average health having screening at age 74 years. Results: Screening 1000 women with average life expectancy at age 74 years for breast cancer resulted in 79 to 96 (range across models) false-positive results, 0.5 to 0.8 overdiagnosed cancer cases, and 0.7 to 0.9 prevented cancer deaths. Although absolute numbers of harms and benefits differed across cancer sites, the ages at which to cease screening were consistent across models and cancer sites. For persons with no, mild, moderate, and severe comorbid conditions, screening until ages 76, 74, 72, and 66 years, respectively, resulted in harms and benefits similar to average-health persons. Limitation: Comorbid conditions influenced only life expectancy. Conclusion: Comorbid conditions are an important determinant of harms and benefits of screening. Estimates of screening benefits and harms by comorbid condition can inform discussions between providers and patients about personalizing screening cessation decisions.

    Related items

    Showing items related by title, author, creator and subject.

    • Should colorectal cancer screening be considered in elderly persons without previous screening?: A cost-effectiveness analysis
      Van Hees, F.; Habbema, D.; Meester, R.; Lansdorp_Vogelaar, Iris; Van Ballegooijen, M.; Zauber, A. (2014)
      Background: The U.S. Preventive Services Task Force recommends against routine screening for colorectal cancer (CRC) in adequately screened persons older than 75 years but does not address the appropriateness of screening ...
    • Estimation of benefits, burden, and harms of colorectal cancer screening strategies: Modeling study for the US preventive services Task Force
      Knudsen, A.; Zauber, A.; Rutter, C.; Naber, S.; Doria-Rose, V.; Pabiniak, C.; Johanson, C.; Fischer, S.; Lansdorp_Vogelaar, Iris; Kuntz, K. (2016)
      Importance: The US Preventive Services Task Force (USPSTF) is updating its 2008 colorectal cancer (CRC) screening recommendations. Objective: To inform the USPSTF by modeling the benefits, burden, and harms of CRC screening ...
    • Consequences of Increasing Time to Colonoscopy Examination After Positive Result From Fecal Colorectal Cancer Screening Test
      Meester, R.; Zauber, A.; Doubeni, C.; Jensen, C.; Quinn, V.; Helfand, M.; Dominitz, J.; Levin, T.; Corley, D.; Lansdorp_Vogelaar, Iris (2016)
      Background & Aims: Delays in diagnostic testing after a positive result from a screening test can undermine the benefits of colorectal cancer (CRC) screening, but there are few empirical data on the effects of such delays. ...
    Advanced search
    Browse
    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin
    Statistics
    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.